Kirkland Assists Impact Therapeutics on its Hong Kong IPO

Kirkland & Ellis represented the joint sponsors, including Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited on the initial public offering of IMPACT Therapeutics, Inc (Impact Therapeutics, HKEX: 7630) on the Main Board of The Stock Exchange of Hong Kong Limited on May 13, 2026.

Impact Therapeutics successfully offered 41,977,000 H Shares at an initial public offering price of HK$20.10 per share and raised approximately HK$844 million prior to the exercise of the 15% over-allotment option, with the Hong Kong public offering tranche oversubscribed by over 2,284 times and international offering tranche oversubscribed by over 24 times.

Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, attracting significant investments from LAV, Tencent and many other prestigious investors.

The Kirkland team included capital markets lawyers Mengyu Lu, George Zheng, Qingyu Wu, Yuchen Han, Sierra Tao, Bill Feng and Qianqian Yu.